Results 11 to 20 of about 21,464 (182)

Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study. [PDF]

Cancer Med
ABSTRACT Background Symptom management in myeloproliferative neoplasms (MPN) remains challenging despite advancements in disease‐directed therapies. This study assessed the impact of demographic, clinical, laboratory and treatment‐related variables on total symptom scores (TSS) and individual symptom scores in patients with polycythemia vera (PV ...
Khan MA, Naqvi SAA, Camoriano JK, Arana Yi CY, Andres JT, Blocher JL, Kosiorek HE, Riaz IB, Palmer JM.   +8 more
europepmc   +2 more sources

Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study. [PDF]

Hemasphere
Abstract Health‐related quality of life (HRQoL) of patients with myeloproliferative neoplasms (MPNs) may be impaired across several domains. In this multicenter observational study, we evaluated HRQoL and symptoms in a cohort of MPN patients with validated measures, including the European Organization for Research and Treatment of Cancer Quality of ...
Caocci G, Costa A, Palandri F, Guglielmelli P, Patriarca A, Iurlo A, Tieghi A, Abruzzese E, Baldi T, Rossi E, Beggiato E, Marchetti M, Fava C, Tomassetti S, Rumi E, Fozza C, Luppi M, Pane F, Bigliardi S, Breccia M, Elli EM, Tartaglia F, Mulas O, Fazi P, Vignetti M, Vannucchi AM, Efficace F.   +26 more
europepmc   +2 more sources

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation. [PDF]

Clin Pharmacol Ther
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Jian W, Yin Y, Chen R, Xue J, Gu J, Du Z, He R, Zhou T.   +7 more
europepmc   +2 more sources

MDS/MPN With SF3B1 Mutation and Thrombocytosis but Without Ring Sideroblasts. [PDF]

Am J Hematol
American Journal of Hematology, Volume 101, Issue 1, Page 129-130, January 2026.
Hazarika B, Bain BJ.
europepmc   +2 more sources

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

Haematologica, 2015
The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia.
Carla Al Assaf, Florence Van Obbergh, Johan Billiet, Els Lierman, Timothy Devos, Carlos Graux, Anne-Sophie Hervent, Jan Emmerechts, Thomas Tousseyn, Pascale De Paepe, Petros Papadopoulos, Lucienne Michaux, Peter Vandenberghe   +12 more
doaj   +1 more source

Thromboembolic complication in Essential Thrombocythemia

The Pan African Medical Journal, 2012
The presenting symptoms of patients with essntial thrombocythemia are quite variable. After detection of thrombocytosis about 13 to 37 percent of patients relate symptoms due to hemorrhagic event, and about 22 to 84 percent of patients report ...
Zahra Mozaheb
doaj   +1 more source

Isolated ten-eleven translocation 2 positive in triple negative essential thrombocythemia: Case report and literature review

SAGE Open Medical Case Reports, 2021
Essential thrombocythemia is one of the famous diseases under the category of myeloproliferative disorder. It is an end result of a genetic mutation of one or more of the most frequent oncogenes such as Janos kinase 2 (JAK2), MPL proto-oncogene ...
Rehab Y AL-Ansari, Dena Al Otaibi, Nourah Al Hudaithi, Leena Abdalla   +3 more
doaj   +1 more source

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source

A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family

Haematologica, 2008
Background Hereditary thrombocythemia is an autosomal dominant disorder with clinical features resembling sporadic essential thrombocythemia.
Kun Liu, Robert Kralovics, Zbigniew Rudzki, Barbara Grabowska, Andreas S. Buser, Damla Olcaydu, Heinz Gisslinger, Ralph Tiedt, Patricia Frank, Krzysztof Okoñ, Anthonie P.C. van der Maas, Radek C. Skoda   +11 more
doaj   +1 more source

Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association?

Hematology Reports, 2018
Vascular events are the most common clinical complication of essential thrombocythemia, leading to sign and symptoms of this disease. There are various sign and symptoms of essential thrombocythemia, such as thrombosis in artery or vein, and enlarged ...
Nata Pratama Hardjo Lugito, Andree Kurniawan, Yohanes Chandra Kurniawan, Enny Yacobus, Edwin Halim   +4 more
doaj   +1 more source